Compare MGYR & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MGYR | GOSS |
|---|---|---|
| Founded | 1922 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.2M | 101.2M |
| IPO Year | 2021 | 2018 |
| Metric | MGYR | GOSS |
|---|---|---|
| Price | $16.10 | $0.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $4.19 |
| AVG Volume (30 Days) | 8.5K | ★ 26.2M |
| Earning Date | 04-29-2026 | 03-17-2026 |
| Dividend Yield | ★ 2.33% | N/A |
| EPS Growth | ★ 26.83 | N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | N/A | ★ $48,471,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $203.01 |
| P/E Ratio | $34.40 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.52 | $0.33 |
| 52 Week High | $20.00 | $3.87 |
| Indicator | MGYR | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 41.80 | 23.42 |
| Support Level | $16.81 | $0.33 |
| Resistance Level | $17.21 | $0.60 |
| Average True Range (ATR) | 0.35 | 0.06 |
| MACD | -0.04 | 0.06 |
| Stochastic Oscillator | 18.95 | 0.00 |
Magyar Bancorp Inc is an independent, community financial services provider offering traditional banking services to individual, business, and government customers. The Company attracts retail deposits through its main office in New Brunswick, New Jersey, and branch offices in Middlesex and Somerset Counties, and invests those funds mainly in commercial and residential real estate loans, commercial business loans, SBA loans, home equity loans and lines of credit, construction and land loans, and investment securities. Revenues are derived mainly from interest on loans and securities and from fees and service charges, with lending relationships focused on small to mid-sized businesses and individual consumers in central and northern New Jersey.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.